PF 07831694
Alternative Names: PF-07831694Latest Information Update: 16 Sep 2024
At a glance
- Originator Pfizer
- Class Bacterial vaccines; Protein vaccines; Subunit vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Clostridium difficile infections
Most Recent Events
- 01 May 2023 Phase-I/II clinical trials in Clostridium difficile infections (Prevention) (unspecified route) before May 2023 (Pfizer pipeline May 2023)